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SUMMARY.-A brief review is presented of the evidence linking the develop-
ment of certain types of neoplasms, and of the malignant lymphomas in par-
ticular, to chronic immunosuppression in animals and man and to the naturally
occurring human immunologic deficiency states. The discussion then focuses
on Hodgkin's disease and considers recent evidence concerning the relation
betweenthe clinicalstage ofthe disease and its associated defect in cell-mediated
immunity. Finally, the prior occurrence of infectious mononucleosis in some
cases ofHodgkin's disease is considered in the context of the hypothesis that the
neoplastic cells of Hodgkin's disease may evolve from a chronic immunologic
reaction, analogous to that of graft-versus-host, stemming from the induction
of antigenic alteration in a subpopulation of lymphocytes by certain types of
non-neoplastic viral infections.
IMMUNOLOGIC theories of carcinogenesis are not new. As early as 1954,
H. N. Green put forward such a theory, which invoked the loss ofspecific cellular
antigen, secondary to binding of tissue proteins by carcinogens, as the essential
cause of neoplasia (Green, 1958). Cajano (1960) proposed a concept of carcino-
genesis which stressed the denaturation or unmasking of autoantigens, which
thereafter behaved as foreign antigens, provoking a
" chain reaction ".
Many of our present-day concepts of molecular biology, of the regulation of
protein synthesis, and of the cellular and molecular mechanisms underlying
immune responses were at that time in a relatively undeveloped state. It would
have been surprising indeed if these early theories had remained valid in the light
of modern knowledge. Nonetheless, they contained the germ of an important
idea, namely, that immunologic mechanisms might contribute significantly to the
genesis ofneoplastic processes.
Two other early theories emphasized the role ofgraft-versus-host reactions of
the type which, under other conditions, may lead to
" homologous wasting
disease", as a sustained stimulus for the proliferative activity of cancerous cells.
One suchtheory, proposed by Tyler (1960), was ageneral one, relating to all types
of cancers. Itpostulated the loss or inactivation of a gene or genes at one or more
of the histocompatibility loci as the initiating event in careinogenesis. Such
gene loss or inactivation was believed to be the consequence of the action of
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chemical, physical, or viral agents. The antigenically depleted tumor cells were
considered capable ofproducing antibody against other cells of the
" host ", and
thus eliciting all of the essential pathological features ofneoplasia. Tyler states:
" On the basis oftheassumption that tumor cells lack one or more
' host
'antigens,
whereby the latter have becomeforeign to it, these cells are chronicallyexposed to
'foreign' antigen. They would then be expected to proliferate indefinitely."
In short, the driving force for tumor cell replication was thought to reside in
their sustained exposure to normal tissue antigens which, because of their own
antigenic depletion, they now perceived as
" foreign ".
A majordifficulty with thistheory is that itrequired that alltypes ofpotential
tumor cells, including those of epithelial and non-lymphoid mesenchymal origin,
be capable of activation to an immunoresponsive state under the special circum-
stances described. AlthoughTylerargued thatnon-lymphoid cellsmightundergo dedifferentiation and thus regain immunologic potentialities ordinarily reserved
for lymphoid cells, no substantiation whatever for this aspect of his theory has
emerged in the intervening decade.
A more specialized and limited theory was that proposed by Professor Sir
David Smithers and myself (Kaplan and Smithers, 1959). We were impressed with the similarity between advanced forms of Hodgkin's disease in man and
homologous graft-versus-host disease in animals with respect to such features as
wasting, anaemia, and lymphocytic depletion. We postulated that tumor cells
stemming from lymphatic tissue might well retain the capacity for immunologic
responses and that under certain conditions such lymphoid tumor cells might become antigenically differentiated from the normal lymphoid cells of the indi-
vidual, perhaps by
" antigenic deletion ". We argued that:
" They would then
acquire the ability to reactagainst anddestroy thepatient's normallymphoid and
other haematopoietic cells. The possibility of a two-way interaction cannot be
excluded but seems less probable."
Such clinically observed sequelae as progressive lymphocytic depletion, hemolytic anaemia, wasting, and increased susceptibility to mycobacterial and
fungal infection were regarded as entirely consonant with the concept that
Hodgkin's disease may be an endogenous counterpart in man ofgraft-versus-host homologous disease in laboratory animals. It was clearly recognized that there
were many gaps in our knowledge at that time which would have to be filled
before this theory could be subjected to rigorous critical analysis. Slightly more than a decade has now elapsed since these concepts were pro- posed. It seemed of interest to examine what we have learned concerning the
role ofimmunologicphenomena incarcinogenesisgenerally and then to focus more
specifically on Hodgkin's disease in an effort to ascertain whether any part of the
Kaplan-Smithers hypothesis has withstood the test of time. The mere fact that
we aregatheredherefor asymposium on
" ImmunosuppressionandCarcinogenesis is, in itself, a sufficient indication of the timeliness of such an analysis.
IMPAIRMENT OF IMMUNOLOGIC SURVEILLANCE MECHANISMS PERMITTING
OUTGROWTH OF TRANSFORMED CLONES
There is now ample evidence that clones of tumor cells attain microscopically detectable dimensions in certain tissues with a frequency which far exceeds the
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the most outstanding example is the prostate gland. The work of Rich (I935),
Franks (I954), and others (Halpert et al., 1963) has revealed the presence of
microcarcinomas in 15 to 30% or more ofprostate glands examined at autopsy in
males over 50 years of age dying of various causes. In contrast, the incidence of
overt prostatic carcinoma in the maximally susceptible age range, 65 to 75 years,
is only about 200 per 100,000 per year (0-2%). In along-term follow-up study of
35 patients in whom microscopic evidence of prostatic cancer was discovered by
chance after prostatic resection for benign obstructive disease, Montgomery et al.
(1961) reported that none developed clinically evident prostatic cancer or died of
prostatic cancer during the ensuing 8 years or more.
The very plausible suggestion has been put forward that immunologic sur-
veillance mechanisms may bepartlyresponsible for theprolongedgrowth restraint
of many of these microscopic tumors, although it is recognized that the endocrine
environment is almost certainly a major factor. On this view, it would be
expected that the experimental induction ofimmunologic insufficiency in labora-
tory animals and the natural occurrence or iatrogenic induction of immunologic
deficiency states in man would be followed by the development of an increased
incidence of neoplasms. This prediction has been confirmed in a variety of
experimental and clinical studies during the past decade. The following is a brief
summary of the major observations to date.
Enhanced,susceptibility to neoplasms in neonatally thymectomized rodent-3
The central role of the thymus gland in the development and maintenance of
immunologic competence has been firmly established. Mice of several strains,
whensubjected tothymectomy inthe neonatalperiod,develop awastingsyndrome
morphologicallyindistinguishable from that inducedbvYraft-versus-hostreactions.
Those that survive for anv length of time exhibit severe immunologic impairment
and a striking enhancement of susceptibility to the induction of neoplasms by
polyoma and other oneogenic viruses (Miller, Ting and Law, 1964; Law and Ting,
1965). It has also beenreported thatthey may exhibit a shorter latentperiod for
tumor induction bv thecarcinogenichydrocarbons,though the differences observed
are notstriking(Miller, Grant andRoe, 1963; GrantandMiller, 1965). Restoration
of immunocompetence by the implantation of isologous thymic grafts simulta-
neously restores resistance to tumor induction by the oncogenic viruses (Law and
Ting, 1965). It is thus clear that the development of the immune surveillance
mechanism may bepreventedby neonatalthymectomy and that the emergence of
virus- and perhaps also of carcinogen-induced tumors is favored under these
conditions.
Immunosuppression by steroids, antimetabolites and antilymphocyteglobulins (ALG)
The yield of tumors induced in mice by polyoma and other oncogenic viruses
can be sharply augmented byimmunosuppressive treatment (Law, 1970; Allison,
1970). Such diverse agents as the adrenocortical steroids, theimmunosuppressive
antimetabolites, such as 6-mereaptopurine or azathioprine, and antilymphocyte
globulins (Vredevoe and Hays, 1969; Law, 1970) have been effective. It has also
been reported that the yield of spontaneous neoplasms may be enhanced in
response to such treatment.
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reason to believe that these immunosuppressive agents are carcinogenic in them-
selves; instead, we seem to be dealing with a situation in which microtumors
induced by DNA tumor viruses, and perhaps by other agents, are permitted to
grow to macroscopic dimensions by inhibition of the restraining influence of the
immune surveillance system. In keeping with this interpretation, it has been
shown that mice rendered susceptible to polyoma-induced neoplasia by immuno-
suppressive treatment can be restored to the normally resistant state by the
injection oflymphoid cells from sensitized, immune donors, but not by lymphoid
cells from normal donors (Allison, 1970).
Certain carcinogenic agents, notably ionizing radiations and the hydrocarbons,
are themselves capable of producing significant injury and impairment of the
immune system (Prehn, 1963; Stjernswdrd, 1965, 1966; Doell et al., 1967). Thus,
such agents may have a dual action; in addition toinducingneoplastic transforma-
tion in clonogenic cells, either directly by mutation or indirectly through the
activation oflatentviruses,they may also createimmunologic conditions favorable
to the survival and sustained proliferation of these newly established, altered
clones. However, two points are puzzling in this context. Firstly, the effect of
thehydrocarbons seems to be limited to a transientdepression ofhumoralantibody
production, whereas one might have expected that the relevant effect would have
been exerted on cell-mediated immunity. Secondly, there is the observation by
Lisco et al. (1958), since confirmed by others, that sublethal whole-body X-ray
exposures, which are undoubtedly immunosuppressive for both the humoral and
cellular systems, fail to potentiate tumor induction by the hydrocarbons.
Limited data indicate that certain of the closely related non-carcinogenic
hydrocarbons lackimmunosuppressive activity (Stjernswdrd, 1966). Moreover, it
has beenreported that a strain of mice known to berefractory to the carcinogenic
action of hydrocarbons were also resistant to their immune suppressant effects
(Stutman, 1969). However, in my view, careful further studies are needed to
ascertain whether it is indeed a valid generalization, at least for certain classes of
carcinogenic compounds, that the active members of the class are all immuno-
suppressive and that the inert ones are not. Rigorous evidence on this point will
be needed before we can confidently conclude that some carcinogens owe their
tumor-inducing activity in part to their capacity to inhibit immune processes.
Neoplasia in rodent-s with chronic graft-versus-host homologous disease
It has long been known that graft-versus-host reactions induce an intense
lymphoproliferative response of the sensitized graft cells (Simonsen et al., 1958),
essentially identical to thelymphoblastic transformation exhibitedbylymphocytes
in vitro after stimulation with specific antigens or nonspecific mitogens, such as
phytohemagglutinin. The proliferative response is followed by a cytocidal attack
upon the normal cells of the host, which is particularly manifest i'n the lymphoid
tissues, leading to their progressive and profound depletion (Schwartz, Upton and
Congdon, 1957; Billingham, 1958; Trentin, 1958; Kaplan and Rosston, 1959).
Although such reactions are usually acutely fatal in infant mice, some animals
survive and slowly recover, though they may give evidence of a continuing smoldering reaction; adult animals tend to exhibit a more chronic, nonlethal
form of the disease. Studying the long-term survivors among a population ofF, hybrid mice in whichgraft-versus-host disease had been inducedby the inoculation624 H. S. KAPLAN
ofparental strain spleen cells, Schwartz and Beldotti (1965) noted the early onset
of a remarkably high incidence of malignant lymphomas, primarily of the type
designated as the
" reticulum cell neoplasm, type B ". An increased incidence of
these tumors was also notedby Walford (1966) in miceinjected with cellsdiffering
at weak histocompatibility loci. Schwartz and Beldotti were initially inclined to
believe that these tumors might derive from the donor cells, in which case they
could beinterpreted as theneoplastic end result of a sustainedimmunoproliferative
and lymphoproliferative stimulus. However, later studies clearly established
that the tumors in their mice were all of host genotype (Armstrong et al., 1970).
Since the Fl hybrid host cells in the system which they used were inherently
incapable of reacting immunologically against the injected parental cells, their
original hypothesis was clearly untenable. Despite the fact that their electron
micrographic search for virus particles in these tumors was consistently unre-
warding, the emergence of a latent oncogenic virus in these chronically immuno-
suppressed animals seems the most plausible alternative mechanism.
Some direct support for this alternative hypothesis has recently been forth-
coming from another source. Stanley et al. (1966) reported the development of a
transplantable malignant lymphoma, designated as 2731/L, in Prince Henry (PH)
mice after inoculation with spleen cells from a 272-day-old PH mouse with chronic
reovirus Type 3 infection. The fact that mice inoculated with reovirus Type 3
develop a
" runtinLr svndrome
" essentially similar to other forms ofhomologous
graft-versus-host disease suggested that this neoplasm may have developed on the
same basis as those observed by Schwartz and Beldotti. Stanley and Keast
(1967) demonstrated the persistent presence of reovirus antigen in the 2731/L
tumor and were inclined to believe that reovirus had played a central role in its
etiology. Recently, however, Levy and Huebner (1970) succeeded in isolating a
murine leukemia virus with immunological characteristics indistinguishable from
those of the Gross-AKR virus from the 2731/L tumor. They suggested that the
tumor was probably induced by this Gross-type murine leukemia virus, and that
the emergence ofthis virus in the spleen cells ofthe original reovirus-infected mice
maywellhave been acceleratedbytheimmunologicimpairmentassociated with the
runting syndrome from which they suffered. Clearly, careful further studies of
this system are indicated, since the model of a nononeogenic virus inducing
autoimmune disease, which in turn is followed by the emergence and oneogenic
activity of a second, latent virus, has intriguing implications for man.
That the lymphoid tumors developing in mice surviving long-sustained
homologous graft-vorsus-host reactions may, however, under certain conditions
beduetothetypeofsustainedimmunoproliferativestimuluspostulatedbySmithers
andmyself, and later by Schwartz andBeldotti, is suggested by a recent report of
Cole and Nowell (1970). Instead ofusingparentalspleen cells andinjecting them
into nonirradiated Fl hybrid mice, these investigators gave a single sublethal
whole-body X-ray dose of 500 R to (C57L x A/He) F, hybrid mice, followed by
the injection ofeither parental (A) lymph node cells (fresh orpreincubated 2 hours
at 37' C. in vitro) or of parental bone marrow, liver, or spleen cells. Although
fresh lymph node cells yielded no tumors, 14 of 26 mice (54%) injected with
preincubatedlymph node cellsdeveloped tumors, an incidence significantly greater
thanthatintheirirradiatedcontrols(17/132,orl3%). Thetumorsweredescribed
as "lymphosarcomas composed of sheets of medium and large lymphocytes,
usually extrathymic in origin and involving the spleen, various lymph nodes,625 IMMUNOLOGIC DISTURBANCE IN HUMAN ONCOGENESIS
kidney, and liver. The most common variant consisted of more undifferentiated
and pleomorphic cells shading into a reticulum cell pattern. Tumors resembling
follicularlymphoma, Hodgkin's disease, andplasmacytoma were observed once or
twice each ". Ofparticular interest was the high incidence of tumors developing
in irradiated mice injected with parental bone marrow, liver, or spleen cells
(13/17, or 76%; 8/10 or 80%; and 6/8 or 75%, respectively).
Several ofthe tumors developing under these conditions were clearly identified
by their capacity to
" take
" and grow in adult A-strain hosts as being of donor
genotype. It would appear, therefore, that the sustained immunoproliferative
stimulation to which the donor cells were subjected must haveplayed a role in the
induction of these lymphoid tumors. This concept also derives support from the
experiments of Metcalf (1961), who observed an increased incidence of reticular
tumors in mice subjected to prolonged antigenic stimulation with Salmonella
flagellar antigen or with bovine serum albumin. Curiously, Cole and Nowell
report that their tumors failed to take in F, hybridrecipients; althoughthey offer
no explanation for this observation, it would suggest, if confirmed, that their
lymphoid tumor cells may have retained their immunocompetence and thus were
capable ofreacting against the C57L histocompatibilitv antigens of the F, hybrid
animals, presumably undergoing suicidal destruction in the process.
TABLEI.-Neoplasia in Congenital Immunologic Deficiency Disorders
(Fraumeni, 1969)
Known or probable No. of cases No. of cases
Disorder No. of cases at risk lymphoma leukemia
1. Ataxia-telangiectasia 200 (?) 13 (3 sibs) 3
2. Wiskott-Aldrich syndrome 60+ (1967) 6 1
3. Agammaglobulinemia, 24 (1963) 1
hypogammaglobulinemia, thymic aplasia ? 2
4. Chediak-Higashi syndrome 36 (1967) 4
Neoplasia in human congenital immunologic deficiency disorders
A widening spectrum of rare congenital immunologic deficiency-states has now
been described. Some of these experiments of nature have been likeiled to the
syndrome induced by neonatalthymectomy in mice, others to thatresulting from
bursectomy in chickens, and some are not yet fully characterized. Isolated case
reports first called attention to the occurrence in some ofthese unfortunatepatients
ofmalignant neoplasms. In the course oftime, careful collations ofthe literature
have yielded enough data to make it clear that patients with congenital immuno-
logic deficiency disorders are indeed at a sharply increased risk ofdeveloping such
neoplasms. From the recent careful analysis by Fraumeni (1969), it is apparent
that the type ofneoplasm most often encountered in this situation is a malignant
lymphoma, rather than a leukemia or epithelial neoplasm, and there is some
evidence to suggest that diffuse histiocytic lymphomas are the principal variant
within the lymphoma category (Table 1). There is still uncertainty, however,
with respect to the peculiar lesion observed in patients with theChediak-Higashi
anomaly; it is clearly some form oflymphoproliferative condition, but whether it
can appropriately be designated a true neoplasm remains uncertain (Dent et al.,
1966).
A remarkable case has recently been reported by von Bernuth et al. (1970) of
Hodgkin's disease encountered at autopsy in a 5-month-old infant with thymic626 H. S. KAPLAN
aplasia and agammaglobulinemia. At Stanford University Medical Center, we
have recently observed two 10-year old male patients with hypogammaglobuli-
nemia (one deficient in IgA, the other in both IgA and IgG, with an abnormal
IgM). These two boys exhibited a chronic reactive lymphadenopathy for several
years, which finally progressed to frankly neoplastic proliferation and dissemina-
tion. Although the initial biopsies were interpreted as Hodgkin's disease in both
instances, due to the presence of large binucleate cells morphologically indis-
tinguishable from Sternberg-Reed cells, careful review of additional biopsy
material in one case and of autopsy material in the other resulted in reclassifica-
tionofthese cases, one as adiffusehistiocyticlymphoma,theother as a
"lymphoma,
unclassified, mostcloselyresem.blinglymphocytepredominantHodgkin'sdisease
TABLEII.-Primary Malignant Neoplasms in Immunosuppressed Renal
Tran8plant Recipients (McKhann, 1969)
Estimated total number of cases recorded in renal transplant
registry
= 2000. Number ofprimary neoplasms reported to
date = 14
Types ofprimary neoplasms reported:
RCSA = 5 Anaplastic Ca = 2
LSA = I Squamous cell Ca = 2
" Lymphoma
"
= 1 Dysgerminoma
= I
Plasmacytoma
= I
"Leukemia" = I
9 5
Estimates of incidence (per 100,000):
All types, All types
all ages age < 40 RCSA
General population 130 8-2 0.9
Renal transplant cases 650 500 400
Malignant neoplasms in immuno8uppressed renal transplant recipient8
The rejection of renal homografts transplanted to patients with severe renal
insufficiency has beenprevented withincreasing successby the chronic administra-
tion ofazathioprine, supplementedintermittentlybysteroids, andtheprolongation
of useful life thus achieved has been gratifying indeed. However, it is now
becoming clear that one of the prices that will have to be paid for this medical
advance is an increased susceptibility to the development ofmalignantneoplasms
in the chronically antigen-exposed, immunosuppressed transplant recipients.
After several isolated case reports had appeared in the literature, McKhann (1969)
distributed a questionnaire to many departments ofsurgery known to have active
renaltransplantation programs. He added the casesreportedby thoseresponding
to the questionnaire to those in the published literature to obtain a total of 14
cases among an estimated total of 2000transplantrecipients. The types oftumor
recorded in this initial survey and the crude estimates of incidence as compared
with that in the general population for all malignancies and for reticulum cell
sarcoma (diffuse histiocytic lymphoma) are summarized in Table 11. This tabula-
tion excludes other cases of cancer which were transplanted inadvertently from., 1) 1. 6111.18 IMMUNOLOGIC DISTURBANCE IN HUMAN ONCOGENESIS
donors, as well as cases in which the transplantrecipients were known to have had
a pre-existing cancer. A particularly striking feature of McKhann's survey was
the occurrence of a very high incidence ofneoplasms in individuals under 40 years
of age.
More recently, Starzl et al. (1970), in a comprehensive analysis of long-term
survival after renal transplantation in man, noted the occurrence of 10 instances
of primary malignant tumors (7 epithelial, 3 mesenchymal) among the 189
patients in their series. After allowance for early deaths, the net number of
patients at risk was estimated at 140, yielding an adjusted tumor incidence of7%.
In the age range represented by their series of patients (5 to 49 years, with an
average of 32years), a cohort from thegeneralpopulationwouldhavebeenexpected
to exhibit a total vearlv cancer incidence of about 0-06%, suggesting that the risk
in their chronicall immunosuppressed renal transplant patients had been en-
hanced about 100-fold (Table 111). Starzl and his colleagues also collated case
reports from the literature and through personal inquiry to obtain a total of 27
TABLE lll.-Primary Malignant Neopla8m8 in Immuno8uppre&3ed Renal
Tran-splant Recipients (Starzl et al., 1970)
N.Neoplasms Incidence, %
CrudeNlo. Net No. __&
at i-isk at risk Epith. Mesench. Total Crude Net
1. Starzl et al. (age range
5-49, average 32 years) 189 140 7 3 10 5- 3 7 I
Expecte(i in cohort of general population 0 06
2. Other published cases 14 13 27
Totals 21 16 37
Histiocytic lymphoma RCSA ") in 12 of 16 mesenchymal tumors; usually eai-ly in onset (ran'go
5-67, average 21 months) aiid with very unfavorable prognosis (11/12 fatal).
additional cases from other departments of surgery. Epithelial neoplasms
account for 21 of the combined total of 37 maligilancies, as might be expected
from their fargreaterprevalence. However, 12 ofthe 16 meseiiehymalneoplasms
were reticulum cell sarcomas (diffuse histiocytic lymphomas). Most of these
occurred in young patients, and tended to develop relatively early in the post-
operative period; the observed latent periods ranged from 5 to 67 months, with an
average of only 21 months. Whereas the epithelial neoplasms exhibited a
reasonably favorable prognosis in response to conventional treatment, the reti-
culum cell sarcomas had an extremely poor prognosis, I I of the 12 recorded cases
terminating fatally.
It should be noted that there is no proof that these neoplasms have developed
solely as a consequence of chronic immunosuppression per -se. These patients
were also chronically exposed to foreign antigen from the donor kidney, and it is
thus entirely possible that the lymphomas, like those in Metcalf's mice, arose in
response to sustainedimmunologic stimulation. Moreover, ifimmune surveillance
is indeed important in restraining the evolution of prostatic microtumors, it is
curious that there have been no prostatic cancers reported to date; however, the
relatively young age of most of the renal transplant recipients may explain their
absence.628 H. S. KAPLAN
POSSIBLE ROLE OF IMMUNOLOGICAL ABNORMALITIES IN THE GENESIS OF
HODGKIN S DISEASE
Impairment of cell-mediated immunity in the early stages ofHodgkin's disease
It is well-known thatpatients withHodgkin's disease often exhibit an increased
susceptibility to mycobacterial, fungal, and other infections and impairment or
absence of immune responses of the cell-mediated type, such as the delayed
hypersensitivity reaction to naturalintradermally inoculated antigens (tuberculin,
mumps, etc.) or chemical contact allergens (dinitrochlorobenzene, DNCB). The
extensive evidence for the existence of such an anergic state in patients with
advanced disease has been carefully reviewed by Aisenberg (1964) and by Chase
(I96Q).
There is little dispute about the existence of such immunologic impairment in
the late stages of the disease; the crucial point relates to whether some degree of
immunologic impairment is also present concomitantly with the earliest stages of
the disease, and thus possibly of relevance to its genesis, or whether the immuno-
logic abnormality is a secondarily acquired manifestation related to extensive
replacement of the lymphoid system by the neoplastic process. Unfortunately,
all of the studies antedating the widespread introduction of lower-extremity
lymphography for the detection of retroperitoneal involvement in Hodgkin's
disease are not useful for this type of analysis, since they are associated with an
excessive staging error.
Accordingly, we must turn to more recent immunologic studies on patients
with previously untreated, biopsy-proven Hodgkin's disease staged with the aidof
lymphography and other modern diagnostic procedures. Only two such studies
arecurrently available. Thefirst, by Brown et al. (1967) from the National Cancer
Institute, deals with a t'otal of 50 patients, all of whom were subjected to intra-
dermal inoculation of abattery of naturalantigens of thedelayedhypersensitivity
type, to contact sensitization with2% DNCB, and to a number ofotherprocedures.
Although the overall response rate ofthe entire group ofpatients was significantly
less than that of concurrent controls, seven of the eight patients with Stage I
Hodgkin's disease yielded a positive response to DNCB and to at least one intra-
dermal antigen. Brown et al. therefore concluded that the immunologic abnor-
mality in Hodgkin's disease is iiot present initially but is acquired secondarily as
the disease progresses.
However, studies by our group at Stanford University Medical Center yielded
results which were sharply at variance with the Bethesda data (Kaplan, 1970).
The rate ofresponse to 2% DNCB among ourpatients with Hodgkin's disease was
remarkably low in all stages (only 36% in Stage 1 versus 8% in Stage IV and 18%
overall). Although the high frequency of anergic responses may well have been
due, at least in part, to the fact that many patients had been started on radiation
therapy before the time of their first DNCB challenge, this criticism could not be
leveled at the data obtained with the natural intradermal antigens in 28 Stage I
cases, all of which were injected before the initiation of any treatment, in which
the yield ofpositive responses was also remarkably low (43% for mumps antigen,
18% for Candida, and only 0 to 7% for tuberculin and the other antigens).
About two years ago, Dr. James R. Eltringham and I initiated a new series of
studies to test the possibility that the 2% concentration of DNCB, which had
been usedby both groups previously, might berelatively insensitive for the detec-629 IMMUNOLOGIC DISTURBANCE IN HUMAN ONCOGENESIS
tion of minor degrees ofimmunologic impairment of the delayed hypersensitivity
type. If so, it would be expected that such impairment would be more delicately
revealed by some lesser concentration of the chemical allergen. Accordingly, we
allocated all new, previously untreated, biopsy-proven cases ofHodgkin's disease
at random to sensitization with one of three different concentrations of DNCB:
0-1. 0-5 and 2-0%. All patients were challenged with 0-1% DNCB about two
weeks later, before the initiation of treatment. In addition, the usual battery of
six intradermal antigens was injected on the day of admission, and reactions
checked at 24 and 4-8 hours. The intradermal antigen reaction was scored as
positive when any one or more ofthe six antigens gave apositive reaction (Eltring-
ham and Kaplan, as yet unpublished).
Confirming our earlier data, only 18 of 98 consecutive patients (18%) in the
new study have yielded a positive intradermal delayed hypersensitivity reaction.
Moreover, there was no recognizable decrease in response rate with increasing
stage of disease. Patients with early, localized disease (Stage IA or IIA) yielded
positive responses in only 5 of 32 cases (16%), whereas those with disseminated
disease (Stage IVA and IVB) yielded responses in 4 of 15 instances (27%).
The DNCB data were even more intriguing, since in this situation the fact of
prior sensitization had been established experimentally. The response rate
among normal controls rose rapidly with increasing sensitizing concentration of
DNCB. Three of 16 controls (I9%) responded to the 0-I% concentration, 24 of
29 (83%) to the0-5% concentration, and 26 of27 (97%) to the2-0% concentration.
There were no responders at all among the 21 patients with various stages of
Hodgkin's disease challenged after sensitization with the 0-1% concentration of
DNCB; this fact and the 19% response rate among controls indicates that this
concentration is too low. At the other end of the concentration spectrum, con-
firming in part the observations of the Bethesda group, 10 of 16 patients (63%)
with disease of Stages IA and IIA responded to the 2-0% concentration, whereas
patients with Stages IIB, III and IV yielded positive reactions in only 4 of 20
instances (20%). The most sensitive concentration proved to be 0-5%, at which
only 3 of II Stage IA and IIA cases (27%) responded, a result which was not
significantly different from that in patients with Stages IIB, III and IV (6 of 26,
or 23%). These response rates to 0-5% DNCB are very significantly deficient,
when compared with the 83% response rate among our normal controls. It has
thus been established convincingly that patients with early, localized Hodgkin's
disease do indeed suffer from a defect in cell-mediated immunity of the delayed
hypersensitivity type, which was masked in the earlier studies because the con-
centration ofDNCB was excessive. These observations callfor further elucidation
ofthe mechanism of the defect and for detailed studies of its evolution in relation
to the course of the disease. It seems essential to find techniques for studying such responses in vitro; in this connection,- recent studies indicating that the
macrophage migration inhibition test and the leukocyte migration inhibition test
may be in vitro correlates of the delayed hypersensitivity reaction provide highly
encouraging avenues for further exploration.
Possiblesignificance of theprior occurrenceofinfectious mononucleosis in some cases
ofHodgkin's disease
There have been severalreported cases ofthe concurrent or prior occurrence of
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(Massey, Lane and Imbriglia, 1953; Kenis, Dustin and Peltzer, 1958; Pacini et al.,
1968), including four casesreported from the Royal Marsden Hospitalby Smithers
11967). During the past several years, I haveattempted to obtain information on
this point in patients with previously untreated, biopsy-proven Hodgkin's disease
seen at Stanford University Medical Center. To date, I have been able to tally a
total of 41 such cases, in 32 of which the prior history of infectious mononucleosis
seems reasonably well-established by the clinical picture and the laboratory
evidence. Essentially all of these cases occurred in patients who were 15 to 30
years of age at the time of admission. The interval between the reported episode
of infectious mononucleosis andbiopsy diagnosis ofHodgkin's disease varied from
a few months to several years.
Patients in the 15- to 30-year-old age bracket comprise 290 (49%) of our
current total of some 590 previously untreated, biopsy-proven cases. It
would thus appear that a prior history of infectious mononucleosis was en-
countered in between 10 and 150/' of our adolescent and young adultpatients with
Hodgkin's disease. It is difficult to know how to compare thisproportion with the
expected attack rate from infectious mononucleosis in a cohort of the general
population. Niederman et al. (1970) recently reported an average yearly attack
rate of 3 to 4% in college students, who are known to be highly susceptible,
whereas Evans (1970) notes an overall hospitalization rate for infectious mono-
nucleosis cases in the United States Armed Forces ofonly 150 per 100,000 (0-15%)
per year, and Pollock (1969) cites an overall annual incidence in the United
Kingdom of about 2 to 5 per 10,000 population, which would be equivalent to
about 10-20/10,000 in the susceptible late adolescent and young adult age group.
Clearly what is needed is a prospective study of patients with documented
infectious mononucleosis who are followed for some years to ascertain their
subsequent incidence of Hodgkin's disease, of other lymphomas, and of other
forms of cancer. The only such study to date is that presented by Dr. Roger
Connelly ofthe Connecticut StateDepartment ofHealth (personal communication;
data presented at the Xth International Cancer Congress, Houston, Texas, May
1970). Infectious mononucleosis and cancer are both reportable diseases in the
State of Connecticut, and it was therefore possible for the Connecticut registry to
conduct aprospectivestudy on some 4516 cases ofinfectious mononucleosis, which
were then cross-matched against some 223,000 cancer cases diagnosed among Connecticut residents. A total of 32 cases of cancer were encountered in 31
patients with a prior history of infectious mononucleosis, as against an expected incidence of 26 cases in a cohort ofthe generalpopulation at risk for a comparable
time interval.
A striking feature was the observation of seven malignant lymphomas, of
which five were instances of Hodgkin's disease. The interval between the
diagnosis of infectious mononucleosis and the subsequent diagnosis of Hodgkin's disease was 3, 77 8. 8 and 10 years. The data strongly suggest that patients with
infectious mononucleosis may be at a significantly increased risk of developing Hodgkin's disease. Other prospective studies of this type are urgently needed.
It isworthy ofnote thatcellsmorphologicallyindistinguishablefromSternberg- Reed cells have been seen in biopsy material from several patients with infectious
mononucleosis (Lukes, Tindle and Parker, 1969; Strum, Park and Rappaport,
1970). Their observation of five such cases led Lukes et al. to speculate that
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liferation, but the initial infectious episode which precedes neoplastic transforma-
tion ".
IfHodgkin's disease is indeed a composite of two or more different entities (as
claimed by MacMahon, 1966) or a single disease entity with several different
contributing etiologies, it is conceivable that one subpopulation of patients in
whom Hodgkin's disease develops is comprised of those who have previously had
infectious mononucleosis. This possibility in turn raises some intriguing etio-
logical considerations, since the EB virus, initially discovered by Epstein and his
associates (1964) in electron micrographs ofcell lines cultured from human Burkitt
lymphomas, has now been strongly implicated in the etiology of infectious mono-
nucleosis (Henle, Henle and Diehl, 1968; Gerber et al., 1968; Niederman et al.,
1968; Evans et al., 1968). It has been shown that anti-EB virus antibody titers
are invariably low in susceptible individuals, rise rapidly to high levels during the
acutephase ofinfectious mononucleosis, and remain elevated for several years after
recovery. Consistent with the possibility that infectious mononucleosis may
precedeHodgkin's disease in asignificantproportion of cases is the recent observa-
tion of an increase in mean geometric EB virus antibody titer in some patients
with Hodgkin's disease, particularly those with the mixed cellularity andlympho-
cytic depletion histopathologic types (Johansson et al., 1970; Levine et al., 1971).
Infection with EB virus has been shown to induce sustained proliferative
activity in normalperipherallymphocytes in vitro, and such cells acquire the same
chromosomal abnormality (constriction of the long arms of chromosome No. 10)
as had previously been observed in cultured Burkitt lymphoma cells (Glade et al.,
1968; Chessin et al., 1968). Although these properties of the virus are quite
significant, its most important property, in terms ofproviding an essential link in
the chain of my argument, is implicit in the recent discovery that cultured lym-
phoid cells frompatients with infectious mononucleosis exhibit alteredantigenicity,
as revealed by their capacity to stimulate DNA synthesis and blastic transforma-
tion responses in fresh lymphocytes taken several months later from the same
individuals (Steel and Hardy, 1970; Junge, Hoekstra and Deinhardt, 1970).
Cell-free extracts ofthe cultured mononucleosis cells contained amembrane-bound,
heat-labile, nondialyzable blastogenic factor which induced the same DNA
synthetic responses in fresh autologous lymphocytes as did the cultured cells
themselves (Junge et al., 1970). Thus, it would appear that at least some of the
lymphoid cells ofpatients acutely infected with EB virus (expressed clinically as
infectiousmononucleosis)undergosustainedantigenicalteration. Parenthetically, it should be pointed out that other, normally nononcogenic and perhaps quite
banal viruses may also exhibit some or all of these properties; there is no a prtori,
reason to assume that they are unique to the EB virus.
It willclearly be ofthegreatestimportance to ascertain whether suchantigenic alterations occur only in vitro or whether some small subpopulation of the
lymphocytes of patients with infectious mononucleosis also become antigenically altered in the original host. Such antigenically altered lymphoid cells, ifindeed] they can be shown to exist in vivo, would be quite analogous to foreign lymphoid cells grafted from some other donor and could be expected to set in motion auto-
immune reactions between the normal and the altered lymphoid-cell populations. It seemslikely that each subpopulation oflymphoid cells wouldperceive the other
as
" foreign
" and thus that the immunological attack would, in allprobability, be
reciprocal.
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Although a small subpopulation ofantigenically altered lymphoid cells would
usually not be expected to survive such an onslaught, it is possible that the
increased proliferative capacity conferred on these cells by EB virus infection
might at least occasionally enable them to replicate at a rate greater than that of
their autoinimune destruction. It is not unreasonable to postulate that such a
sustainedhigh rate ofproliferation, particularly in the presence ofthe chromosomal
abnormality previously induced by the EB virus, might well render these cells
susceptible to the occurrence of additional chromosomal abnormalities which,
whenever they conferred any proliferative advantage, would tend to undergo
strongpositive selectionbythe continueddriving force ofthe autoimmune reaction.
Thus, truly neoplastic lymphoid cells might evolve as the end-stage consequence
of aninitiallynon-neoplastic viral infectioncapable ofinducing antigenic alteration
(and perhaps also chromosomal instability) in a subpopulation of lymphocytes.
The cases eventuating in neoplasia would be those in which the altered lymphoid
cells replicated fast enough to survive and become clinically manifest; the great
majority of cases would be expected to be aborted by the complete destruction of
these cells in the course of the autoimmune cytocidal warfare.
In this model system, theneoplasticlymphoid cells would be expected to retain
some degree ofimmunologic competence and to exhibit the capability ofengaging
in immunologic reactions against their normal counterparts. Some support for
this postulate is to be found in the very interesting case of Hodgkin's disease
observed by Sinks and Clein (1966), in which a Sternberg-Reed cell leukemia
occurred, with over 90% ofthe lymphoid cells in the peripheral blood being of the
Sternberg-Reed type. It was demonstrated that these cells were capable of
exhibiting typical blastic traiisformation responses after stimulation with phyto-
liemagglutinin in vitro, suggesting that they shared at least this attribute of
immunocompetence with normal lymphoid cells.
Iftechniques can be developed for isolating and concentrating Sternberg-Reed
and other Hodgkin's cells from involved lymph nodes, it may become possible to
test cells from other patients in response to phytohemagglutinin and to specific
antigens in vitro to ascertain more convincingly whether they are indeed immuno-
competent. Firm evidence on this point would strongly support the postulate
that the neoplastic lymphoid cells continue to engage in autoimmune warfare
against the normallymphoid cellpopulation. If so, theprogressive and inexorable
lymphocytic depletion observed during the course of unsuccessfully treated
Hodgkin's disease, though also due in part to the ravages of radiotherapy and
chemotherapy, may result from the same type of cytocidal interaction as is
characteristic of the graft-versus-host homologous wasting syndrome.
Viewed in this perspective, it seems entirely possible that the Kaplan-Smithers
hypothesis may pertain not only to the advanced stages ofHodgkin's disease, but
to its genesis as well, at least in those instances in which virus-induced antigenic
alterations of a subpopulation of lymplioid cells set the stage for an endogenous analogue of the graft-versus-host wasting reaction.
In summary, we stand today very much farther down the road of understand-
ing some of the mechanisms whereby a variety ofnaturally-occurring and experi-
mentally-inducedimmunological abnormalities may lead toneoplasia inlaboratory
animals and man. Admittedlv, much ofthe evidence is stillincomplete, and some
of it merely circumstantial. Nonetheless, we now possess a much more well-
defined conceptual framework for the design of future clinical and laboratoryIMMUNOLOGIC DISTURBANCE IN HUMAN ONCOGENESIS 633
investi ations aimed at the elucidation of the responsible mechanisms. It seems
likely that the most prevalent situation will be that in which neoplasms induced
byfranklyoncogenic viruses arepermitted to emerge as a consequence ofsustained
immunosuppressive or immunologically deficient states. However, we must also
remain alert to the possibility that far more subtle and complex interactions may
occur in which initially nononeogenic viruses, by inducing antigenic and other
alterations insubpopulations oflymphoidcells, may initiate sustained autoimmune
lymphoproliferative responses leading ultimately to Hodgkin's disease and other
forms oflymphoid neoplasia.
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